These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8562259)

  • 1. [The treatment of hypertension in patients with a metabolic disorder].
    Dal Palù C; Semplicini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():130S-132S. PubMed ID: 8562259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)].
    Klein W
    Z Kardiol; 1992 Jun; 81(6):295-302. PubMed ID: 1353932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1 blockers: antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored.
    Waite MA
    J Intern Med Suppl; 1991; 735():113-7. PubMed ID: 1675053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
    Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
    Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive treatment and its implications on lipoprotein metabolism of patients in care by a hypertension and diabetes program in Brazil.
    Martins RD; Alves Rde S; Silva GG; Martins N; Vasconcelos S; Assreuy A; Martins A; Goretti Queiroz M
    Acta Med Port; 2008; 21(6):567-74. PubMed ID: 19331790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence of lipid disorders and their course after blood pressure control in essential arterial hypertension].
    Sánchez M; Sobrino J; Coca A; de la Sierra A; Lluch MM; Aguilera MT; Picado MJ; Urbano-Márquez A
    Med Clin (Barc); 1992 Apr; 98(15):568-71. PubMed ID: 1602866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum ghrelin levels and disturbances of the lipid profile in patients with acromegaly.
    Jaskula M; Wasko R; Komarowska H; Dziubandowska A; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):245-55. PubMed ID: 19675514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic neutrality in nitrendipine therapy.
    Mancini M; Marotta T; Ferrara LA
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S30-3. PubMed ID: 1723452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.